Artra Group Corporation 3Q Earnings Flash
Profit at the A-COMS business doubled, lifting operating income to roughly 2.8x the prior-year level. Guidance was raised for the third time this fiscal year. The next focus areas are whether equipment sales can be sustained from 4Q onward and the SIbot launch.
Key Positives From The 3Q Results
These results show the payoff from divesting the Toy Sales business and concentrating on A-COMS. 3Q cumulative operating income reached JPY 251M (+182.9% YoY). A-COMS segment profit expanded to JPY 257M (+105.8% YoY). Stronger sales of equipment for self-pay treatments and revenue growth in all six support areas delivered profit growth that more than offset the smaller revenue base.
- A-COMS Margin Expansion: Revenue of JPY 2,051M (+18.3%), with margin rising to 12.6% (7.2% in the prior year, our estimate). Operating leverage from top-line growth drove the profit increase.
- Gross Margin and Cost Control: Gross profit margin was 38.9% (+3.9pt, company disclosure), and SG&A fell by JPY 207M (-23.0%). Both the gross margin gain and lower SG&A contributed to profit growth.
- Quarterly Acceleration: 3Q standalone operating income was approx. JPY 170M (our estimate), up from JPY 17M in 1Q and JPY 64M in 2Q. Excluding toys, the underlying earnings power of A-COMS is now clearly visible.
- Balance Sheet Strengthening: Interest-bearing debt was cut from JPY 1,050M to JPY 699M, and the equity ratio rose to 52.1% (+11.0pt). The shift to a net cash position gives the company capacity to invest in new businesses.
- Guidance Raised: Full-year operating income guidance was raised from JPY 160M to JPY 300M, the third upgrade this fiscal year. 3Q cumulative results already exceed the full-year forecast as of August.
Key Concerns From The 3Q Results
The main earnings driver was equipment and consumables sales (JPY 632M, +32.6%), which are largely transactional. Growth in the subscription-based Artra Billing Service was limited to +4.2%. Backing out from revised guidance, implied 4Q operating income is approx. JPY 48M, a sharp drop from approx. JPY 170M in 3Q standalone. Investors need to gauge how sustainable current profit levels are.
- Net Income Decline: Net income was JPY 117M (-34.3%). This reflects a JPY 130M loss on the sale of Pelican shares, compounded by the absence of the prior year's JPY 92M gain on sale of investment securities.
- Implied 4Q Revenue Step-Down: Implied 4Q revenue from full-year guidance is approx. JPY 575M (our estimate), below 3Q standalone revenue of JPY 806M. The company has not disclosed whether 3Q included one-off large orders.
- Slow Recurring Revenue Growth: Artra Billing Service grew +4.2% and Nursing Care Support +4.1%. The industry's structural problem of declining reimbursable treatment fees remains a drag.
- Dilution: Exercise of stock acquisition rights increased shares outstanding from 10,287,000 to 10,887,000 (+5.8%). Diluted EPS fell to JPY 10.63.
- SIbot Upfront Costs: The company plans to spend approx. JPY 150M in total on SIbot. Management has indicated that costs such as depreciation will precede revenue in the early stages, which could weigh on FY12/2027 earnings.
Focus Areas / Items To Monitor Going Forward
- Sustainability of Equipment and Consumables Sales: Whether proprietary equipment such as the Artra Gauge establishes itself as a source of recurring demand will determine the profit run-rate.
- 4Q Actuals Versus Revised Guidance: If profit holds near the 3Q standalone level, there is room to beat guidance. That would raise the starting point for next year's plan.
- Progress on SIbot and the REMED Partnership: The MOU with REMED runs for one year. The timing of individual contracts will be a key test of monetizing the expansion layer.
- The assumptions behind the sharp drop in the 4Q plan (operating income approx. JPY 48M, revenue approx. JPY 575M) versus 3Q standalone, and whether 3Q included one-off factors
- The share of proprietary equipment in equipment and consumables sales, its gross margin, and the status of the order pipeline
- Net additions to A-COMS client clinics (approx. 3,000), the number of switch-over contracts won, and ARPU trends
- The remaining volume of stock acquisition rights and the outlook for further dilution
- The timeline for SIbot monetization, the scale of cost burden in FY12/2027, and the expected investment payback
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Revenue | JPY 2,425M | -14.2% |
| └ A-COMS Business | JPY 2,051M | +18.3% |
| └ Toy Sales Business | JPY 373M | -65.9% |
| Gross Profit | JPY 945M | -4.5% |
| └ Gross Profit Margin | 38.9% | +3.9pt |
| SG&A | JPY 693M | -23.0% |
| Operating Income | JPY 251M | +182.9% |
| └ Operating Income Margin | 10.4% | +7.2pt (our estimate) |
| Recurring Profit | JPY 258M | +166.6% |
| Extraordinary Income | JPY 1M | -98.7% |
| Extraordinary Losses | JPY 131M | +JPY 129M YoY |
| └ Loss on Sale of Shares of Affiliated Companies | JPY 130M | - |
| Quarterly Net Income Attributable to Owners of Parent Company | JPY 117M | -34.3% |
| EPS | JPY 11.32 | -35.1% |
The revenue decline reflects the deconsolidation of the Toy Sales business (Pelican) at end-March 2026, with only January–March results recorded. The JPY 162M increase in operating income comprises +JPY 132M from higher A-COMS profit and +JPY 30M from a narrower loss in Toy Sales (company disclosure). The net income decline was driven by a one-off non-cash loss booked in 1Q (per the company) and the absence of the prior year's gain on sale.
Performance By Business Segment
The A-COMS business now generates virtually all consolidated operating income. Toy Sales was deconsolidated at end-March, so from 4Q onward the company will operate A-COMS as its sole business.
Segment Performance Table
| Segment | Revenue | YoY | Operating Income | YoY | Margin |
|---|---|---|---|---|---|
| A-COMS Business | JPY 2,051M | +18.3% | JPY 257M | +105.8% | 12.6% |
| Toy Sales Business | JPY 373M | -65.9% | JPY -7M | Loss narrowed (prior year: JPY -37M) | -1.9% |
| Consolidated | JPY 2,425M | -14.2% | JPY 251M | +182.9% | 10.4% |
*Revenue represents sales to external customers. Margins are our estimates.
- Equipment and Consumables Sales: JPY 632M (+32.6%). Reducing dependence on reimbursable treatment fees is an industry-wide challenge. Against this backdrop, sales activity and seminars drove higher sales of self-pay treatment equipment. The division is now the largest within A-COMS, at roughly 30% of segment revenue.
- HONEY-STYLE: JPY 95M (+71.6%). User clinics for this review and booking system for acupuncture and judo therapy clinics continue to grow. The business remains small but is sustaining high growth.
- Other: JPY 104M (+151.0%). Expansion into adjacent areas contributed.
- Honetsugi Chain: JPY 417M (+7.1%). Driven by franchise recruitment and higher sales at directly operated clinics.
- A-COMS Quarterly Revenue: Approx. JPY 597M in 1Q, JPY 649M in 2Q and JPY 806M in 3Q (our estimates). Growth accelerated to +24% QoQ in 3Q.
- Toy Sales Business: JPY 373M (-65.9%). All Pelican shares were transferred on March 31, so only January–March results were recorded. The segment loss narrowed to JPY -7M, and this structural source of losses has been removed.
- Artra Billing Service / Nursing Care Support: JPY 471M (+4.2%) and JPY 329M (+4.1%). Revenue grew, but only in the single digits. The company continues to win newly opened clinics and switch-over contracts. Even so, recurring revenue is growing more slowly than equipment sales.
Progress Versus Full-Year Guidance
Against revised full-year guidance, 3Q cumulative progress stands at 83.8% for operating income and 82.2% for recurring profit. This exceeds progress against full-year actuals at the same point last year (revenue 72.0%, operating income 62.9%, our estimates). If operating income holds near the 3Q standalone level, it could exceed the approx. JPY 48M needed in 4Q. Net income progress is only 65.3%. Hitting the full-year target requires approx. JPY 63M of net income in 4Q, more than the implied 4Q recurring profit.
| Item | Value (3Q Cumulative) | Full-Year Forecast | Progress Rate |
|---|---|---|---|
| Revenue | JPY 2,425M | JPY 3,000M | 80.8% |
| Operating Income | JPY 251M | JPY 300M | 83.8% |
| Recurring Profit | JPY 258M | JPY 315M | 82.2% |
| Net Income | JPY 117M | JPY 180M | 65.3% |
| EPS | JPY 11.32 | JPY 17.02 | 66.5% |
- No Company Commentary: The company has not commented on seasonality. Last year's quarterly operating income was JPY -19M in 1Q, JPY 44M in 2Q, JPY 63M in 3Q and JPY 52M in 4Q (our estimates), skewed to the second half. However, those figures reflect the former business mix, which included Toy Sales.
Changes To Guidance
Full-year guidance was raised, the third upgrade this fiscal year after revisions on 5/15 and 8/7. All A-COMS divisions exceeded prior-year levels, led by equipment and consumables sales. Operating income and recurring profit are now expected to more than double from last year's actuals.
- Revenue: Raised from JPY 2,700M to JPY 3,000M (+11.1%)
- Operating Income: Raised from JPY 160M to JPY 300M (+87.5%)
- Recurring Profit: Raised from JPY 165M to JPY 315M (+90.9%)
- Net Income: Raised from JPY 15M to JPY 180M
- Reasons for Revision: Removal of losses through deconsolidation of Toy Sales, strong equipment and consumables sales (+32.6% on a 3Q cumulative basis) and SG&A efficiencies (-23.0% on the same basis). The JPY 130M loss on sale of affiliate shares is expected to be absorbed by core earnings.
Commentary On Shareholder Returns
The annual dividend forecast is unchanged at JPY 0.00 (no dividend last year either). There was no mention of share buybacks. Retained earnings turned positive at JPY 114M after the deficit was eliminated. However, the company intends to fund new businesses from internal resources. For now, it is prioritizing balance sheet strength and growth investment.
Financial Position
Total assets were reduced to JPY 3,648M (-11.6% vs. prior fiscal year-end) through debt repayment and lower merchandise inventory. The equity ratio rose to 52.1%. Cash and deposits exceed interest-bearing debt, keeping the company in a net cash position. Note, however, that cash includes funds corresponding to collection agency deposits received.
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Cash and Deposits | JPY 1,442M | +27.8% vs. prior fiscal year-end |
| Shareholders' Equity | JPY 1,902M | +12.2% vs. prior fiscal year-end |
| Interest-Bearing Debt | JPY 699M | -33.5% vs. prior fiscal year-end (our estimate) |
| └ Long-Term Borrowings | JPY 523M | -34.4% vs. prior fiscal year-end |
| └ Current Portion of Long-Term Borrowings | JPY 140M | -32.2% vs. prior fiscal year-end |
| └ Bonds (Including Current Portion) | JPY 35M | -22.2% vs. prior fiscal year-end |
| Merchandise | JPY 239M | -59.9% vs. prior fiscal year-end; reflects deconsolidation of the Toy Sales business |
| Operating Loans | JPY 405M | -2.1% vs. prior fiscal year-end |
| Collection Agency Deposits Received | JPY 612M | +0.6% vs. prior fiscal year-end |
| EBITDA | JPY 318M | Operating income + depreciation (JPY 66M), 9-month cumulative, +90.0% YoY (our estimate) |
| Metric | Value | Notes |
|---|---|---|
| Net Debt/EBITDA | Net Cash | Cash and deposits exceed interest-bearing debt by JPY 743M (our estimate) |
| Debt/Equity | 0.37x | 0.62x at prior fiscal year-end (our estimate) |
| Interest Coverage Ratio | 30.6x | Operating income ÷ interest expense; 8.5x in the prior-year period (our estimate) |
| Equity Ratio | 52.1% | 41.1% at prior fiscal year-end (company disclosure) |
Disclosures Released Alongside The Earnings Announcement
- 2026/11/13Full-year guidance raised to revenue of JPY 3,000M, operating income of JPY 300M and net income of JPY 180M (the third upgrade this fiscal year). The company highlighted the recovery in core earnings power.
- 2026/11/133Q earnings presentation. Outlines a three-layer growth structure (A-COMS foundation → expansion into healthcare → robotics) and an overview of SIbot.
Major Announcements During The Quarter
- 2026/09/10Approved for listing on the Nagoya Stock Exchange Main Market. The dual listing alongside the TSE Standard Market aims to broaden the investor base.
- 2026/10/29Board resolved to establish SIbot as a joint venture with RBB (51% owned by the company; a specified subsidiary). Approx. JPY 150M in total will be invested in humanoid robot sales and implementation support and in building a data factory. Operations are scheduled to begin in 2026.
Large-Shareholding Filings / Material Proposals Over The Past Year
- Milestone Capital Management: 26.9%→25.7% (2026/10/30) - Pure investment
- Milestone Capital Management: 27.2%→26.9% (2026/10/15) - Pure investment
- Milestone Capital Management: 28.2%→27.2% (2026/10/08) - Pure investment
- Milestone Capital Management: 29.3%→28.2% (2026/09/16) - Pure investment
- Milestone Capital Management: 29.6%→29.3% (2026/08/17) - Pure investment
- Milestone Capital Management: 30.7%→29.6% (2026/07/31) - Pure investment
- Milestone Capital Management: 30.7%→30.7% (2026/07/08) - Pure investment (change in composition of shares held)
- Remedia: New→5.0% (2026/07/01) - Pure investment (amendment report)
- Milestone Capital Management: New→30.7% (2026/01/05) - Pure investment
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.